Fig. 1From: Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysisPRISMA flow diagram of the study process. PRISMA, Preferred Reporting Items for Systematic review and Meta-analysisBack to article page